# The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors

> **NCT02660034** · PHASE1 · COMPLETED · sponsor: **BeiGene** · enrollment: 229 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **BIOLOGICAL:** Tislelizumab
- **DRUG:** Pamiparib

## Key facts

- **NCT ID:** NCT02660034
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-02
- **Primary completion:** 2020-09-09
- **Final completion:** 2020-09-09
- **Target enrollment:** 229 (ACTUAL)
- **Last updated:** 2021-12-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02660034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02660034, "The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02660034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*